This analysis reveals that inhibiting SSBP1 enhances ferroptosis and improves sorafenib effectiveness in liver cancer, highlighting its potential as a prognostic biomarker.
Key Points
Inhibiting SSBP1 improves sensitivity to sorafenib, reducing liver cancer progression and enhancing treatment efficacy.
Higher SSBP1 expression correlates with poor prognosis, indicating its potential as a prognostic biomarker in liver cancer.
Mitochondrial metabolism alterations in liver cancer contribute to increased reactive oxygen species production, impacting treatment effectiveness.
Bioinformatics analysis identified SSBP1 as a potential driver of tumor growth, warranting further investigation for therapeutic targeting.